Medic East Africa’s Post

Yesterday, I joined the 37th EURORDIS-Rare Diseases Europe ERTC Workshop panel discussion, and I wanted to share some of the things that stuck with me. We drilled into how we can improve access to #RareDisease treatments in Europe - a critical task requiring collective action to ensure treatments reach patients: 1️⃣ Innovation: We must stimulate more breakthrough and incremental innovation. 2️⃣ Collaboration: Trust and new thinking are crucial to define flexible approval, access pathways, and evidence requirements to drive innovation. 3️⃣ Policy: More flexible, patient-centred regulatory frameworks and reimbursement models that account for the cost of care versus the cost of treatment are needed. Let's keep working together as a community to ensure everyone gets access to the treatment they need when they need it. #HealthCareInnovation

Today’s 37th Workshop of the #EURORDIS Round Table of Companies saw over 130 registrants, representing 19 countries, gather to discuss the importance of transforming foresight into action to support the development of affordable and accessible treatments for rare diseases patients! 🗣️ Here are the key learnings: - Early dialogues between patients, regulators, HTA bodies, payers, and developers are key to fostering innovation. Check out our recommendation for an orphan drug development plan: https://lnkd.in/eSQWhn9Z - Mechanisms such as PRIME and MoCA are important examples of these collaborations but trust must remain at the heart of these relationships in order to foster the type of changes we want to see. - To overcome global healthcare challenges and reach the goal of 1000 new treatments by 2030, we as a community must continue to drive change and turn good will into action. Transparent public-private relationships between patient advocates, industry, academia and decision makers are essential to shape policies that best serve the interests of our community. Learn more about the ERTC on our website. Tomasz Grybek, Kevin Loth #collaboration #industry #relationships #workshop #cooperation #meeting

Healthcare savings and better access for patients arrived with biosimilar competition in Europe, but potential voids may come with changing levels of activity. IQVIA explores the current situation and the likely future. https://bit.ly/47pGClZ

South Asia's diverse population presents a unique challenge in healthcare. One-size-fits-all medication approaches often fall short, population-specific data, and integrating pharmacogenomics into clinical trials is essential for drug safety and efficacy across diverse backgrounds. In this editorial article, Vinod Scaria and I discuss how uncovering pharmacogenomic variations specific to South Asian populations will not only bridge the representation gaps in clinical trials but also offer precise guidance for the optimal and efficient utilization of particular medications. https://lnkd.in/gVjxey5Q Karkinos Healthcare

🇳🇿 New Zealand HCPs Share Insights on Biosimilar Transition 🇳🇿 A new survey sheds light on the experiences of healthcare providers (HCPs) in New Zealand who transitioned patients from the originator adalimumab (Humira) to a biosimilar in 2022. Read the full study: https://lnkd.in/ePBAjf3M

As healthcare shifts to become more patient centric, it’s more important than ever for pharma companies to identify which levers they need to activate as part of the launch strategy. In this on-demand demo, our experts dive into the complexities associated with drug launches, discuss common challenges across rare diseases and show how ZAIDYN™ Health Insights can bolster your understanding of the market landscape to pinpoint winning strategies. https://bit.ly/3xKuW1m

Heading to #ISPORAnnual? We’ll be there! HEOR and #MarketAccess are evolving, with changes in HTA, acceleration in the use of RWE and increased reactions to cost-containment measures. At #OxfordPharmaGenesis, we’re contributing to conversations about how these changes affect value demonstration strategies. We are experts in advising on payer strategy, developing payer evidence and supporting payer evaluation. We’re looking forward to discussing how we could support you! 🙌 #OxfordPharmaGenesis

As healthcare shifts to become more patient centric, it’s more important than ever for pharma companies to identify which levers they need to activate as part of the launch strategy. In this on-demand demo, our experts dive into the complexities associated with drug launches, discuss common challenges across rare diseases and show how ZAIDYN™ Health Insights can bolster your understanding of the market landscape to pinpoint winning strategies. https://bit.ly/4f0sMLB

As healthcare shifts to become more patient centric, it’s more important than ever for pharma companies to identify which levers they need to activate as part of the launch strategy. In this on-demand demo, our experts dive into the complexities associated with drug launches, discuss common challenges across rare diseases and show how ZAIDYN™ Health Insights can bolster your understanding of the market landscape to pinpoint winning strategies. https://bit.ly/3W8V6CK

As healthcare shifts to become more patient centric, it’s more important than ever for pharma companies to identify which levers they need to activate as part of the launch strategy. In this on-demand demo, our experts dive into the complexities associated with drug launches, discuss common challenges across rare diseases and show how ZAIDYN™ Health Insights can bolster your understanding of the market landscape to pinpoint winning strategies. https://bit.ly/4cEUYSI